supplies of the direct thrombin inhibitor lepirudin (Refludan) dwindle over the next few months
You'll see supplies of the direct thrombin inhibitor lepirudin (Refludan) dwindle over the next few months.
It's not a drug shortage. Lepirudin is being discontinued by the manufacturer for business reasons...not safety concerns.
This leaves just one first-line agent for preventing and treating thrombosis in patients with heparin-induced thrombocytopenia (HIT).
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote